51
|
Nam DH, Ge X. Development of a periplasmic FRET screening method for protease inhibitory antibodies. Biotechnol Bioeng 2013; 110:2856-64. [PMID: 23703626 DOI: 10.1002/bit.24964] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/12/2013] [Revised: 03/29/2013] [Accepted: 05/13/2013] [Indexed: 12/19/2022]
Abstract
Proteases play critical roles in numerous physiological processes and thus represent one of the largest families of potential pharmaceutical targets. Previous failure of broad-spectrum small molecule inhibitors toward tumorigenic metalloproteinases in clinical trials emphasizes that selectivity is the key for a successful protease-inhibition therapy. With exquisite specificity, antibody-based inhibitors are emerging as promising therapeutics. However, the majority of current antibody selection technologies are based on binding and not on inhibition. Here, we report the development of a function-based inhibitory antibody screening method, which combines a simple periplasmic preparation and an ultra sensitive FRET assay, both processes are amenable to high-throughput applications. Using this method, inhibitory antibodies can be rapidly distinguished from non-inhibitory clones with satisfactory Z-factors. Coupled with ELISA, this method also provides a fast semi-quantitative estimation of IC₅₀ values without antibody purification. We expect this technology to greatly facilitate the generation of highly selective biologic inhibitors, targeting many proteases that are important to medical research and therapeutic development.
Collapse
Affiliation(s)
- Dong Hyun Nam
- Department of Chemical and Environmental Engineering, University of California, Riverside, Bourns Hall B309, 900 University Ave., Riverside, California, 92521
| | | |
Collapse
|
52
|
Ingvarsen S, Porse A, Erpicum C, Maertens L, Jürgensen HJ, Madsen DH, Melander MC, Gårdsvoll H, Høyer-Hansen G, Noel A, Holmbeck K, Engelholm LH, Behrendt N. Targeting a single function of the multifunctional matrix metalloprotease MT1-MMP: impact on lymphangiogenesis. J Biol Chem 2013; 288:10195-204. [PMID: 23413031 DOI: 10.1074/jbc.m112.447169] [Citation(s) in RCA: 47] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022] Open
Abstract
The group of matrix metalloproteases (MMPs) is responsible for multiple processes of extracellular matrix remodeling in the healthy body but also for matrix and tissue destruction during cancer invasion and metastasis. The understanding of the contributions from each individual MMP, both in healthy and pathological events, has been complicated by the lack of specific inhibitors and the fact that some of the potent MMPs are multifunctional enzymes. These factors have also hampered the setup of therapeutic strategies targeting MMP activity. A tempting target is the membrane-associated MT1-MMP, which has well-documented importance in matrix degradation but which takes part in more than one pathway in this regard. In this report, we describe the selective targeting of a single function of this enzyme by means of a specific monoclonal antibody against MT1-MMP, raised in an MT1-MMP knock-out mouse. The antibody blocks the enzyme ability to activate proMMP-2 without interfering with the collagenolytic function or the general proteolytic activity of MT1-MMP. Using this antibody, we have shown that the MT1-MMP-catalyzed activation of proMMP-2 is involved in the outgrowth of cultured lymphatic endothelial cells in a collagen matrix in vitro, as well as in lymphatic vessel sprouting assayed ex vivo. This is the first example of the complete inactivation of a single function of a multifunctional MMP and the use of this strategy to pursue its role.
Collapse
Affiliation(s)
- Signe Ingvarsen
- Finsen Laboratory, Rigshospitalet/BRIC, DK-2200 Copenhagen N, Denmark
| | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
53
|
Laios A, Mohamed BM, Kelly L, Flavin R, Finn S, McEvoy L, Gallagher M, Martin C, Sheils O, Ring M, Davies A, Lawson M, Gleeson N, D’Arcy T, d’Adhemar C, Norris L, Langhe R, Saadeh FA, O’Leary JJ, O’Toole SA. Pre-Treatment of platinum resistant ovarian cancer cells with an MMP-9/MMP-2 inhibitor prior to cisplatin enhances cytotoxicity as determined by high content screening. Int J Mol Sci 2013; 14:2085-103. [PMID: 23340649 PMCID: PMC3565367 DOI: 10.3390/ijms14012085] [Citation(s) in RCA: 20] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/07/2012] [Revised: 01/05/2013] [Accepted: 01/06/2013] [Indexed: 02/08/2023] Open
Abstract
Platinum resistance is a major cause of treatment failure in ovarian cancer. We previously identified matrix metalloproteinase 9 (MMP-9) as a potential therapeutic target of chemoresistant disease. A2780cis (cisplatin-resistant) and A2780 (cisplatin-sensitive) ovarian carcinoma cell lines were used. The cytotoxic effect of MMP-9/MMP-2 inhibitor, (2R)-2-[(4-Biphenylsulfonyl) amino]-3 phenylpropionic acid (C21H19NO4S) alone or in combination with cisplatin was determined using high content screening. Protein expression was examined using immunohistochemistry and ELISA. Co-incubation of cisplatin and an MMP-9/MMP-2 inhibitor, (2R)-2-[(4-Biphenylsulfonyl) amino]-3 phenylpropionic acid (C21H19NO4S) resulted in significantly greater cytotoxicity as compared to either treatment alone in a cisplatin resistant MMP-9 overexpressing cell line; A2780cis. In addition, pre-incubating with MMP-9i prior to cisplatin further enhances the cytotoxic effect. No significant difference was observed in MMP-9 protein in tissue but a trend towards increased MMP-9 was observed in recurrent serum. We propose that MMP-9/MMP-2i may be utilized in the treatment of recurrent/chemoresistant ovarian cancers that overexpress MMP-9 mRNA but its role in vivo remains to be evaluated.
Collapse
Affiliation(s)
- Alexandros Laios
- Department of Obstetrics and Gynaecology, Trinity College Dublin, Trinity Centre for Health Sciences, St. James’s Hospital, Dublin 8, Ireland; E-Mails: (A.L.); (L.K.); (L.M.E.); (N.G.); (T.D.A.); (L.N.); (R.L.); (F.A.S.)
- Department of Histopathology, Trinity College Dublin, Sir Patrick Duns Research Laboratory, St. James’s Hospital and The Coombe Women and Infants University Hospital, Dublin 8, Ireland; E-Mails: (R.F.); (S.F.); (M.G.); (C.M.); (O.S.); (M.R.); (C.D.A.)
| | - Bashir M. Mohamed
- Department of Clinical Medicine, Trinity College Dublin, Trinity Centre for Health Sciences, St. James’s Hospital, Dublin 8, Ireland; E-Mails: (B.M.M.); (A.D.)
| | - Lynne Kelly
- Department of Obstetrics and Gynaecology, Trinity College Dublin, Trinity Centre for Health Sciences, St. James’s Hospital, Dublin 8, Ireland; E-Mails: (A.L.); (L.K.); (L.M.E.); (N.G.); (T.D.A.); (L.N.); (R.L.); (F.A.S.)
| | - Richard Flavin
- Department of Histopathology, Trinity College Dublin, Sir Patrick Duns Research Laboratory, St. James’s Hospital and The Coombe Women and Infants University Hospital, Dublin 8, Ireland; E-Mails: (R.F.); (S.F.); (M.G.); (C.M.); (O.S.); (M.R.); (C.D.A.)
| | - Stephen Finn
- Department of Histopathology, Trinity College Dublin, Sir Patrick Duns Research Laboratory, St. James’s Hospital and The Coombe Women and Infants University Hospital, Dublin 8, Ireland; E-Mails: (R.F.); (S.F.); (M.G.); (C.M.); (O.S.); (M.R.); (C.D.A.)
| | - Lynda McEvoy
- Department of Obstetrics and Gynaecology, Trinity College Dublin, Trinity Centre for Health Sciences, St. James’s Hospital, Dublin 8, Ireland; E-Mails: (A.L.); (L.K.); (L.M.E.); (N.G.); (T.D.A.); (L.N.); (R.L.); (F.A.S.)
- Department of Histopathology, Trinity College Dublin, Sir Patrick Duns Research Laboratory, St. James’s Hospital and The Coombe Women and Infants University Hospital, Dublin 8, Ireland; E-Mails: (R.F.); (S.F.); (M.G.); (C.M.); (O.S.); (M.R.); (C.D.A.)
| | - Michael Gallagher
- Department of Histopathology, Trinity College Dublin, Sir Patrick Duns Research Laboratory, St. James’s Hospital and The Coombe Women and Infants University Hospital, Dublin 8, Ireland; E-Mails: (R.F.); (S.F.); (M.G.); (C.M.); (O.S.); (M.R.); (C.D.A.)
| | - Cara Martin
- Department of Histopathology, Trinity College Dublin, Sir Patrick Duns Research Laboratory, St. James’s Hospital and The Coombe Women and Infants University Hospital, Dublin 8, Ireland; E-Mails: (R.F.); (S.F.); (M.G.); (C.M.); (O.S.); (M.R.); (C.D.A.)
| | - Orla Sheils
- Department of Histopathology, Trinity College Dublin, Sir Patrick Duns Research Laboratory, St. James’s Hospital and The Coombe Women and Infants University Hospital, Dublin 8, Ireland; E-Mails: (R.F.); (S.F.); (M.G.); (C.M.); (O.S.); (M.R.); (C.D.A.)
| | - Martina Ring
- Department of Histopathology, Trinity College Dublin, Sir Patrick Duns Research Laboratory, St. James’s Hospital and The Coombe Women and Infants University Hospital, Dublin 8, Ireland; E-Mails: (R.F.); (S.F.); (M.G.); (C.M.); (O.S.); (M.R.); (C.D.A.)
| | - Anthony Davies
- Department of Clinical Medicine, Trinity College Dublin, Trinity Centre for Health Sciences, St. James’s Hospital, Dublin 8, Ireland; E-Mails: (B.M.M.); (A.D.)
| | - Margaret Lawson
- Department of Histopathology, St. James’s Hospital, Dublin 8, Ireland; E-Mail:
| | - Noreen Gleeson
- Department of Obstetrics and Gynaecology, Trinity College Dublin, Trinity Centre for Health Sciences, St. James’s Hospital, Dublin 8, Ireland; E-Mails: (A.L.); (L.K.); (L.M.E.); (N.G.); (T.D.A.); (L.N.); (R.L.); (F.A.S.)
| | - Tom D’Arcy
- Department of Obstetrics and Gynaecology, Trinity College Dublin, Trinity Centre for Health Sciences, St. James’s Hospital, Dublin 8, Ireland; E-Mails: (A.L.); (L.K.); (L.M.E.); (N.G.); (T.D.A.); (L.N.); (R.L.); (F.A.S.)
| | - Charles d’Adhemar
- Department of Histopathology, Trinity College Dublin, Sir Patrick Duns Research Laboratory, St. James’s Hospital and The Coombe Women and Infants University Hospital, Dublin 8, Ireland; E-Mails: (R.F.); (S.F.); (M.G.); (C.M.); (O.S.); (M.R.); (C.D.A.)
| | - Lucy Norris
- Department of Obstetrics and Gynaecology, Trinity College Dublin, Trinity Centre for Health Sciences, St. James’s Hospital, Dublin 8, Ireland; E-Mails: (A.L.); (L.K.); (L.M.E.); (N.G.); (T.D.A.); (L.N.); (R.L.); (F.A.S.)
| | - Ream Langhe
- Department of Obstetrics and Gynaecology, Trinity College Dublin, Trinity Centre for Health Sciences, St. James’s Hospital, Dublin 8, Ireland; E-Mails: (A.L.); (L.K.); (L.M.E.); (N.G.); (T.D.A.); (L.N.); (R.L.); (F.A.S.)
- Department of Histopathology, Trinity College Dublin, Sir Patrick Duns Research Laboratory, St. James’s Hospital and The Coombe Women and Infants University Hospital, Dublin 8, Ireland; E-Mails: (R.F.); (S.F.); (M.G.); (C.M.); (O.S.); (M.R.); (C.D.A.)
| | - Feras Abu Saadeh
- Department of Obstetrics and Gynaecology, Trinity College Dublin, Trinity Centre for Health Sciences, St. James’s Hospital, Dublin 8, Ireland; E-Mails: (A.L.); (L.K.); (L.M.E.); (N.G.); (T.D.A.); (L.N.); (R.L.); (F.A.S.)
| | - John J. O’Leary
- Department of Histopathology, Trinity College Dublin, Sir Patrick Duns Research Laboratory, St. James’s Hospital and The Coombe Women and Infants University Hospital, Dublin 8, Ireland; E-Mails: (R.F.); (S.F.); (M.G.); (C.M.); (O.S.); (M.R.); (C.D.A.)
| | - Sharon A. O’Toole
- Department of Obstetrics and Gynaecology, Trinity College Dublin, Trinity Centre for Health Sciences, St. James’s Hospital, Dublin 8, Ireland; E-Mails: (A.L.); (L.K.); (L.M.E.); (N.G.); (T.D.A.); (L.N.); (R.L.); (F.A.S.)
- Department of Histopathology, Trinity College Dublin, Sir Patrick Duns Research Laboratory, St. James’s Hospital and The Coombe Women and Infants University Hospital, Dublin 8, Ireland; E-Mails: (R.F.); (S.F.); (M.G.); (C.M.); (O.S.); (M.R.); (C.D.A.)
| |
Collapse
|
54
|
Honibald EN, Mathew S, Padmanaban J, Sundaram E, Ramamoorthy RD. Perioceutics: Matrix metalloproteinase inhibitors as an adjunctive therapy for inflammatory periodontal disease. JOURNAL OF PHARMACY AND BIOALLIED SCIENCES 2012; 4:S417-21. [PMID: 23066302 PMCID: PMC3467883 DOI: 10.4103/0975-7406.100315] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/01/2011] [Revised: 01/02/2012] [Accepted: 01/26/2012] [Indexed: 11/15/2022] Open
Abstract
Matrix metalloproteinases (MMPs) form a group of more than 20 zinc-dependent enzymes that are crucial in the degradation of the main components in the extracellular matrix, and thereby play important roles in cell migration, wound healing, and tissue remodeling. MMPs have outgrown the field of extracellular matrix biology and have progressed toward being important regulatory molecules in inflammation, and hence are key components in the pathogenesis of periodontitis. This rise in status has led to the development of MMP inhibitors which can act as switches or delicate tuners in acute and chronic inflammation and the regenerative phase after inflammation. The new challenge in MMP research is to better understand the complex role these enzymes play in periodontal disease and to design inhibitors that are successful in the clinic. Perioceutics or the use of the pharmacological agents specifically developed to manage periodontitis is an interesting and emerging aid in the management of periodontal diseases along with mechanical debridement. The purpose of this review is to provide an introduction to MMPs and their inhibitors, the pathologic effects of a disturbance in the functions of enzyme cascades in balance with natural inhibitors, and highlight on the adjunctive use of MMP inhibitors in periodontal therapy and some of the current challenges with an overview of what has been achieved till date.
Collapse
Affiliation(s)
- Esther Nalini Honibald
- Department of Periodontics, KSR Institute of Dental Science and Research, KSR Kalvi Nagar, Thokkavadi (PO), Tiruchengode,Namakkal (Dt), Tamil Nadu, India
| | | | | | | | | |
Collapse
|
56
|
Pérez-Sayáns M, Suárez-Peñaranda JM, Gayoso-Diz P, Barros-Angueira F, Gándara-Rey JM, García-García A. Tissue inhibitor of metalloproteinases in oral squamous cell carcinomas - a therapeutic target? Cancer Lett 2012; 323:11-19. [PMID: 22484495 DOI: 10.1016/j.canlet.2012.03.040] [Citation(s) in RCA: 18] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/08/2012] [Accepted: 03/30/2012] [Indexed: 11/30/2022]
Abstract
Matrix metalloproteinases (MMPs) are proteases responsible for remodeling the extracellular matrix (ECM) and enabling spreading and metastasis of tumor cells, a common phenomenon in oral squamous cell carcinomas (OSCC). They are strongly blocked by several inhibitors, among which we must highlight, for their specificity and potency, the endogenous tissue inhibitors of metalloproteinases (TIMP-1, -2, -3 and -4). The goal of this paper is to describe the expression of TIMPs in OSCC, determining their relation with clinical, histological and prognostic factors, delving into OSCC regulation mechanisms and discussing the use of exogenous TIMPs to treat this type of tumors. Expression of TIMPs in OSCC is higher in tumors than in normal tissue, which correlates with an increase of metastatic risk and regional lymph node affectation. Although some metalloproteinases inhibitors (MMIs) have shown promising results in the treatment of these tumors, their use in OSCC has not been widely tested; and although some indirect MMIs, like COX-2 inhibitors, flavonoids and endostatin seem to have beneficial effects on the invasive capacity of OSCC through regulation of MMPs and TIMP levels, routine clinical use has not been accepted yet.
Collapse
Affiliation(s)
- Mario Pérez-Sayáns
- Oral Medicine, Oral Surgery and Implantology Unit, Faculty of Medicine and Dentistry, Instituto de Investigación Sanitaria de Santiago (IDIS), Santiago de Compostela, Spain; Entrerríos s/n, Santiago de Compostela C.P. 15782, Spain.
| | - José Manuel Suárez-Peñaranda
- Servicio de Anatomia Patológica, Hospital Clinico Universitario de Santiago, Choupana s/n, Santiago de Compostela C.P. 15706, Spain.
| | - Pilar Gayoso-Diz
- Clinical Epidemiology and Biostatistics Unit, Hospital Clínico Universitario de Santiago de Compostela, Instituto de Investigación Sanitaria de Santiago (IDIS), A Choupana s/n, Santiago de Compostela 15706, Spain.
| | - Francisco Barros-Angueira
- Unidad de Medicina Molecular, Fundación Pública Galega de Medicina Xenómica, Edificio de Consultas planta-2, Hospital Clinico Universitario, Santiago de Compostela C.P. 15706, Spain.
| | | | - Abel García-García
- Oral Medicine, Oral Surgery and Implantology Unit, Faculty of Medicine and Dentistry, Instituto de Investigación Sanitaria de Santiago (IDIS), Santiago de Compostela, Spain; Entrerríos s/n, Santiago de Compostela C.P. 15782, Spain.
| |
Collapse
|
57
|
Newby AC. Matrix metalloproteinase inhibition therapy for vascular diseases. Vascul Pharmacol 2012; 56:232-44. [PMID: 22326338 DOI: 10.1016/j.vph.2012.01.007] [Citation(s) in RCA: 123] [Impact Index Per Article: 10.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/15/2011] [Revised: 01/23/2012] [Accepted: 01/25/2012] [Indexed: 10/25/2022]
Abstract
The matrix metalloproteinases (MMPs) are 23 secreted or cell surface proteases that act together and with other protease classes to turn over the extracellular matrix, cleave cell surface proteins and alter the function of many secreted bioactive molecules. In the vasculature MMPs influence the migration proliferation and apoptosis of vascular smooth muscle, endothelial cells and inflammatory cells, thereby affecting intima formation, atherosclerosis and aneurysms, as substantiated in clinical and mouse knockout and transgenic studies. Prominent counterbalancing roles for MMPs in tissue destruction and repair emerge from these experiments. Naturally occurring tissue inhibitors of MMPs (TIMPs), pleiotropic mediators such as tetracyclines, chemically-synthesised small molecular weight MMP inhibitors (MMPis) and inhibitory antibodies have all shown effects in animal models of vascular disease but only doxycycline has been evaluated extensively in patients. A limitation of broad specificity MMPis is that they prevent both matrix degradation and tissue repair functions of different MMPs. Hence MMPis with more restricted specificity have been developed and recent studies in models of atherosclerosis accurately replicate the phenotypes of the corresponding gene knockouts. This review documents the established actions of MMPs and their inhibitors in vascular pathologies and considers the prospects for translating these findings into new treatments.
Collapse
|
58
|
Abstract
Osteoarthritis (OA) is characterized by the breakdown of articular cartilage that is mediated in part by increased production of matrix metalloproteinases (MMPs) and aggrecanases (ADAMTS), enzymes that degrade components of the cartilage extracellular matrix. Efforts to design synthetic inhibitors of MMPs/ADAMTS have only led to limited clinical success. In addition to pharmacologic therapies, physiologic joint loading is widely recommended as a nonpharmacologic approach to improve joint function in osteoarthritis. Clinical trials report that moderate levels of exercise exert beneficial effects, such as improvements in pain and physical function. Experimental studies demonstrate that mechanical loading mitigates joint destruction through the downregulation of MMPs/ADAMTS. However, the molecular mechanisms underlying these effects of physiologic loading on arthritic joints are not well understood. We review here the recent progress on mechanotransduction in articular joints, highlighting the mediators and pathways in the maintenance of cartilage integrity, especially in the prevention of cartilage degradation in OA.
Collapse
Affiliation(s)
- Daniel J. Leong
- Department of Orthopaedic Surgery, Albert Einstein College of Medicine/Montefiore Medical Center, Bronx, New York
- Department of Radation Oncology, Albert Einstein College of Medicine/Montefiore Medical Center, Bronx, New York
- Oncophysics Research Institute, Albert Einstein College of Medicine/Montefiore Medical Center, Bronx, New York
| | - John A. Hardin
- Department of Orthopaedic Surgery, Albert Einstein College of Medicine/Montefiore Medical Center, Bronx, New York
| | - Neil J. Cobelli
- Department of Orthopaedic Surgery, Albert Einstein College of Medicine/Montefiore Medical Center, Bronx, New York
| | - Hui B. Sun
- Department of Orthopaedic Surgery, Albert Einstein College of Medicine/Montefiore Medical Center, Bronx, New York
- Department of Radation Oncology, Albert Einstein College of Medicine/Montefiore Medical Center, Bronx, New York
- Oncophysics Research Institute, Albert Einstein College of Medicine/Montefiore Medical Center, Bronx, New York
| |
Collapse
|
59
|
Bauvois B. New facets of matrix metalloproteinases MMP-2 and MMP-9 as cell surface transducers: outside-in signaling and relationship to tumor progression. Biochim Biophys Acta Rev Cancer 2011; 1825:29-36. [PMID: 22020293 DOI: 10.1016/j.bbcan.2011.10.001] [Citation(s) in RCA: 242] [Impact Index Per Article: 18.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/15/2011] [Revised: 10/03/2011] [Accepted: 10/04/2011] [Indexed: 12/14/2022]
Abstract
This review focuses on matrix metalloproteinases (MMPs)-2 (gelatinase A) and -9 (gelatinase B), both of which are cancer-associated, secreted, zinc-dependent endopeptidases. Gelatinases cleave many different targets (extracellular matrix, cytokines, growth factors, chemokines and cytokine/growth factor receptors) that in turn regulate key signaling pathways in cell growth, migration, invasion, inflammation and angiogenesis. Interactions with cell surface integral membrane proteins (CD44, αVβ/αβ1/αβ2 integrins and Ku protein) can occur through the gelatinases' active site or hemopexin-like C-terminal domain. This review evaluates the recent literature on the non-enzymatic, signal transduction roles of surface-bound gelatinases and their subsequent effects on cell survival, migration and angiogenesis. Gelatinases have long been drug targets. The current status of gelatinase inhibitors as anticancer agents and their failure in the clinic is discussed in light of these new data on the gelatinases' roles as cell surface transducers - data that may lead to the design and development of novel, gelatinase-targeting inhibitors.
Collapse
Affiliation(s)
- Brigitte Bauvois
- INSERM U872, Centre de Recherche des Cordeliers, Université Pierre et Marie Curie, Université Paris Descartes, Paris, France.
| |
Collapse
|